Thorat_2026_CNS.Neurol.Disord.Drug.Targets__

Alzheimer's disease (AD) is a neurological disorder that affects adults worldwide. AD is also an essential geriatric disorder because of its significant emotional and economic impact on individuals, their loved ones, and society. Traditional treatments do not account for the genetic heterogeneity among patients, leading to variable therapeutic effects. Pharmacogenomics customizes medicinal therapies based on a person's genetic profile, enhances efficacy, and minimizes side effects. This review examines how genetic variables affect responses to drugs in neurodegenerative illnesses and the potential for pharmacogenomics to improve treatment. This review explores the possibility of pharmacogenomics in clinical practice, including ethical and data integration concerns. Furthermore, this review discusses the hypothesis of the effects of mutant presenilin on AD therapeutics, along with several clinical trial drugs, their effects, and possible treatment opportunities. Additionally, this review provides insights into prospects and potential treatment strategies for AD. The use of pharmacogenetic/pharmacogenomic procedures in AD studies and clinical trials can help generate cost-effective medications while also increasing therapeutic safety and efficacy.